ObsEva S.A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical trials. This drug aims to mitigate pain associated with endometriosis and reduce heavy menstrual bleeding stemming from uterine fibroids in pre-menopausal women.